



**The Glyoxalase System, Inhibition of Thioredoxin
Reductase and Use of Methylene Blue as Drug
Development Strategies against the Malarial
Parasite *Plasmodium falciparum***

A thesis submitted in fulfilment of the German degree
doctor rerum naturalium (Dr. rer. nat.)

of the

Faculty of Biology and Chemistry (FB 08)

of

Justus-Liebig-University, Giessen, Germany

presented by

Monique B. Akoachere

from

Cameroon

- 2005 -

The work reported in this thesis was carried out during the period of April 2002 to September 2005 at the Institute of Nutritional Biochemistry, Interdisciplinary Research Centre, Justus-Liebig-University, Giessen, Germany. The work was supported by the German Academic Exchange Service (DAAD) and supervised by Prof. Dr. med. Katja Becker-Brandenburg and Prof. Dr. Albrecht Bindereif.

Dean:	Prof. Dr. Juergen Mayer Institute of Biological Didactics Faculty of Biology and Chemistry Justus-Liebig-University Giessen Karl-Glöckner-Strasse 21, 35394 Giessen
First Referee:	Prof. Dr. Albrecht Bindereif Institute of Biochemistry Faculty of Biology and Chemistry Justus-Liebig-University Giessen Heinrich-Buff-Ring 58, 35392 Giessen
Second Referee:	Prof. Dr. med. Katja Becker-Brandenburg Institute of Nutritional Biochemistry Faculty of Agricultural and Nutritional Sciences, Home Economics and Enviromental Management Justus-Liebig-University Giessen Heinrich-Buff-Ring 26-32, 35392 Giessen
Additional Jury Member:	Prof. Dr. Rudolf Geyer Biochemistry Institute University Teaching Hospital Justus-Liebig-University Giessen Friedrichstrasse 24, 35392 Giessen

Berichte aus der Biochemie

Monique B. Akoachere

**The Glyoxalase System, Inhibition of Thioredoxin
Reductase and Use of Methylene Blue as Drug
Development Strategies against the Malarial
Parasite *Plasmodium falciparum***

D 26 (Diss. Universität Giessen)

Gedruckt mit Unterstützung des Deutschen Akademischen Austauschdienstes

Shaker Verlag
Aachen 2005

Bibliographic information published by Die Deutsche Bibliothek

Die Deutsche Bibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data is available in the internet at <http://dnb.ddb.de>.

Zugl.: Giessen, Univ., Diss., 2005

Copyright Shaker Verlag 2005

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publishers.

Printed in Germany.

ISBN 3-8322-4687-8

ISSN 1434-5536

Shaker Verlag GmbH • P.O. BOX 101818 • D-52018 Aachen

Phone: 0049/2407/9596-0 • Telefax: 0049/2407/9596-9

Internet: www.shaker.de • eMail: info@shaker.de

Dedication

To my family

Confirmation

This thesis is the original work of Akoachere Monique Bate. Other sources of information have been properly quoted. The work has not been used to obtain any other university degrees.

Acknowledgements

To begin, I would like to say that I am extremely thankful to Professors Albrecht Bindereif and Katja Becker-Brandenburg for not only giving me the opportunity to carry out my PhD project at the University of Giessen, Germany, but also for supervising and standing by the project during the entire course. To Katja, I wish to say thank you for your continuous scientific and personal encouragement especially in difficult times. Special thanks go to Prof. Heiner Schirmer for his support and collaboration throughout the PhD project.

I would also like to thank the “Deutscher Akademischer Austauschdienst” (DAAD) for the unrelentless financial support throughout the PhD project and during the German language course at the Goethe Institute of Göttingen.

I would also like to thank the entire working group of Professor Becker-Brandenburg for the friendly working environment. To Stefan Rahlfs and Rimma Iozef, I will say thank you for your support and collaboration on the glyoxalase system. Elisabeth, I do appreciate the training I got from you in the cell culture laboratory. To Xu Ying and Taiwo Ojurongbe, I say thank you for helping to carry out statistical analysis of the results obtained from drug combination assays. To the other PhD colleagues in the lab, Julia Bolt-Ulschmidt, Christine Nickel, Sabine Urig, Marcel Deponte, Sasa Koncarevic, Kathrin Buchholz and Boniface Mailu, I say thanks for all the ideas I have gained from you during our numerous discussions. To the other co-workers of the group, Tammy, Ulli, Beate, Marina, Marita, Johanna, Simone, Nicole, Annette and Doris, I really do appreciate whatever help – in one way or the other – I received from you.

I would like to thank the entire Akoachere family for their encouragement with respect to the PhD project. Special thanks go to my brother Ashu Akoachere for helping me find my supervisor Katja and also for his struggle concerning the DAAD scholarship. To my Dad, E. B. Akoachere, whose dream had always been that I become a “doctor” right from the time I was still a kid, I am happy that I have been able to fulfil this dream of yours while you are still alive. To my Mum, Felicia Akoachere, I wish to thank you for your steadfast prayers and kindly support for all your kids. To my other brethren, Alfred, George, Johnson, Barbara, Oben, Nkongho, Arrey, Ayuk, Paula, Juliet and Kate, I say thanks for being there for me.

To friends (Sylvia, Adrienne), I say thanks for the encouragement you gave me in all aspects of life. To wellwishers most of whom I got to know during my stay in Giessen, thank you all for the good times we shared.

Last and most important, my sincere appreciation goes to God Almighty for His continuous love, protection and guidance over me.

Original Publications

1. Andricopulo, A. D., Nickel, C., Krogh, R., **Akoachere, M.**, McLeish, M. J., Davioud-Charvet, E., Kenyon, G. L., Arscott, D. L., Williams, C. H. Jr. and Becker, K. (2005). Specific inhibitors of *Plasmodium falciparum* thioredoxin reductase as potential antimalarial agents. *Submitted to Bioorganic and Medicinal Chemistry Letters*.
2. Andricopulo, A. D., **Akoachere, M.**, Krogh, R., Nickel, C., McLeish, M. J., Davioud-Charvet, E., Kenyon, G. L., Arscott, D. L., Williams, C. H. Jr. and Becker, K. (2005). Thioredoxin reductase of the malarial parasite *Plasmodium falciparum* – Inhibitor development as a basis for novel chemotherapeutic strategies. *Flavins and Flavoproteins* in press.
3. **Akoachere, M.**, Buchholz, K., Fischer, E., Burhenne, J., Haefeli, W., Schirmer, H. and Becker, K. (2005). *In vitro* assessment of methylene blue on chloroquine sensitive and resistant *Plasmodium falciparum* strains reveals synergistic action with artemisinins. *Antimicrobial Agents and Chemotherapy* **49**: 4592-4597.
4. **Akoachere, M.**, Iozef, R., Rahlfs, S., Deponte, M., Mannervik, B., Creighton, D. J., Schirmer, H., Becker, K. (2005) Characterization of the glyoxalases of the malarial parasite *Plasmodium falciparum* and comparison with their human counterparts. *Biological Chemistry*, **386**: 41-52.
5. Cho-Ngwa, F., **Akoachere, M.** and Titanji, V. P. (2003). Sensitive and specific serodiagnosis of riverblindness using *Onchocerca ochengi* antigens. *Acta Tropica* **89**: 25-32.

Abstracts in Meetings

- **Akoachere, M.**, Buchholz, K., Fischer, E., Burhenne, J., Haefeli, W., Schirmer, H. and Becker, K. (2005). Methylene blue in antimalarial drug combinations. *In vitro* effects on *Plasmodium falciparum* strains. 54th Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH), Washington D. C., USA.
- **Akoachere, M.**, Iozef, R., Rahlfs, S., Deponte, M., Schirmer, R. H. and Becker, K. (2005). Characterization of the glyoxalases of the malarial parasite *Plasmodium falciparum* and comparison with their human counterparts. Drug development seminar, Bernhardt Nocht Institute, Hamburg.
- Andricopulo, A. D., Nickel, C., Krogh, R., **Akoachere, M.**, McLeish, M. J., Davioud-Charvet, E., Kenyon, G. L., Arscott, D. L., Williams, C. H. Jr. and Becker, K. (2005). Novel inhibitors of the thioredoxin reductase from *Plasmodium falciparum* as potential antimalarial agents. 15th International Symposium on Flavins and Flavoproteins, Shonan Village, Japan.
- **Akoachere, M. B.**, Iozef, R., Rahlfs, S., Deponte, M., Schirmer, R. H. and Becker, K. (2005). Characterization of the glyoxalases of the malarial parasite *Plasmodium falciparum* and comparison with their human counterparts. First Annual BiolMalPar Conference Meeting, EMBL, Heidelberg.
- Rahlfs, S., Iozef, R., **Akoachere, M.**, Schirmer, R. H. and Becker, K. (2004). Glyoxalase I of the malarial parasite *Plasmodium falciparum*: Evidence for subunit fusion. Jahrestagung der Deutschen Gesellschaft für Parasitologie, Würzburg.
- **Akoachere, M.**, Iozef, R., Rahlfs, S., and Becker, K. (2003). The glyoxalase system of the malarial parasite *Plasmodium falciparum*. MBML (Molecular Biology and Medicine of the Lung) Retreat Program, Marburg.

Table of Contents

Dedication.....	III
Confirmation.....	IV
Acknowledgements.....	V
Original and abstract publications.....	VI
Table of Contents.....	VII
List of Figures.....	XI
List of Tables.....	XIII
List of Schemes.....	XIV
Abbreviations.....	XV
Summary.....	XVII
Zusammenfassung.....	XIX
1 Introduction and Rationale	1
1.1 The disease	1
1.1.1 The <i>Anopheles</i> vector	2
1.1.2 Life cycle of the parasite	3
1.1.3 Pathophysiology of the disease	4
1.1.4 Diagnosis of malaria.....	4
1.1.5 Control.....	6
1.1.5.1 Control through prevention of transmission.....	6
1.1.5.2 Control through therapy	7
1.1.5.3 Control through vaccines.....	11
1.2 Rationale of the study.....	13
1.2.1 The glyoxalase system.....	13
1.2.1.1 Non-glyoxalase metabolism of methylglyoxal.....	17
1.2.2 The thioredoxin reductase system	19
1.2.3 Methylene blue in antimalarial therapy.....	20
1.2.4 Other aspects of the PhD project	23
1.2.4.1 Glutathionylation of thioredoxin of <i>P. falciparum</i>	23
1.2.4.2 Lipoamide dehydrogenases of <i>P. falciparum</i>	24
1.3 Objectives of the study	25
1.3.1 The glyoxalase system.....	25
1.3.2 The thioredoxin reductase of <i>P. falciparum</i>	25

1.3.3	Methylene blue in antimalarial chemotherapy	25
2	Materials and methods.....	26
2.1	Materials.....	26
2.1.1	Chemicals	26
2.1.2	Malaria drugs.....	26
2.1.3	Enzymes	26
2.1.4	Antibodies.....	27
2.1.5	Kits	27
2.1.6	Instruments	27
2.1.7	Biological materials.....	28
2.1.7.1	cDNA libraries and erythrocytes	28
2.1.7.2	Plasmids.....	28
2.1.7.3	<i>Escherichia coli</i> cells.....	28
2.1.7.4	Strains of <i>P. falciparum</i>	29
2.1.8	Buffers and solutions.....	29
2.1.8.1	Solutions for DNA electrophoresis.....	29
2.1.8.2	Solutions for protein electrophoresis.....	29
2.1.8.3	Solutions for western blotting.....	30
2.1.8.4	Extraction of parasites from infected red blood cells.....	31
2.1.9	Growth medium.....	31
3	Methods	32
3.1	Gene identification.....	32
3.2	Polymerase chain reaction (PCR)	32
3.3	Cloning and overexpression of genes.....	33
3.4	Site-directed mutagenesis	34
3.5	Purification of glyoxalase enzymes	34
3.6	SDS-PAGE	37
3.7	Western blotting	37
3.8	Concentration of proteins	38
3.9	Determination of protein concentrations	38
3.9.1	A ₂₈₀ method	38
3.9.2	Bradford method.....	39
3.10	Enzymatic assays	39
3.11	Inhibition studies	41

3.12	Glutathionylation assays	42
3.13	Metal ion analysis	42
3.14	Structure prediction of glyoxalase enzymes	42
3.15	Protein crystallization	43
3.15.1	Crystallization screening	43
3.15.2	Crystallization optimization	44
3.16	Cell culture experiments	45
3.16.1	Synchronization	45
3.16.2	Studies on MB uptake	46
3.16.3	Determination of enzymatic activity from parasitic extracts.....	46
3.16.4	Drug susceptibility tests	47
3.16.4.1	WHO microtest.....	47
3.16.4.2	Semi-automated microdilution method	49
3.16.4.3	Drug combination assays.....	51
3.16.5	Statistics.....	52
4	Results.....	53
4.1	The glyoxalase system.....	53
4.1.1	Recombinant production of <i>P. falciparum</i> glyoxalases	53
4.1.2	Kinetic characterization.....	56
4.1.3	Inhibition studies	58
4.1.4	Metal ion analysis.....	60
4.1.5	Cell culture experiments.....	60
4.1.6	Crystallization experiments	61
4.1.7	<i>Plasmodium falciparum</i> glyoxalase structure predictions.....	62
4.2	The inhibition of PfTrxR	67
4.2.1	Kinetic analyses on isolated enzymes	67
4.2.2	Effects of the inhibitors on <i>P. falciparum</i> in culture	68
4.3	The <i>in vitro</i> antimalarial effects of MB.....	69
4.3.1	Stage-specificity of MB action	69
4.3.2	Studies on MB uptake	71
4.3.3	Effects of MB upon combination with other drugs	71
4.3.3.1	Combination of MB with clinically-used antimalarials	71
4.3.3.2	Combination of MB with artemisinins	72
4.4	The characterization of PfLipDHs.....	77

4.5	Glutathionylation of PfTrx	77
5	Discussion	80
5.1	The glyoxalase system	81
5.2	The thioredoxin system	84
5.3	Methylene blue in antimalarial chemotherapy	86
5.4	Glutathionylation of PfTrx	90
6	References.....	91
6.1	General references.....	91
6.2	Websites.....	102

List of Figures

Figure 1:	Geographic distribution of malaria around the world.	1
Figure 2:	Life cycle of the parasite <i>Plasmodium falciparum</i>	4
Figure 3:	Blood stages of <i>P. falciparum</i> (Malaria Manual, 2003).	5
Figure 4:	Diagram of <i>P. falciparum</i> trophozoite residing in an erythrocyte.	7
Figure 5:	Structures of selected antimalarial drugs.	9
Figure 6:	Malaria life cycle and vaccine targets.	12
Figure 7:	Reactions of the glyoxalase system.	14
Figure 8:	Physiological formation of 2-oxoaldehydes.	16
Figure 9:	Chemical development of antimalarial drugs from methylene blue.	21
Figure 10:	Structure of the S-(<i>N</i> -hydroxy- <i>N</i> -arylcarbamoyl)glutathiones.	42
Figure 11:	Diagram of hanging drop method.	44
Figure 12:	Semi-automated microdilution method: Arrangement of drugs on a 96 well plate.	50
Figure 13:	Alignment of N- and C-terminal halves of <i>P. falciparum</i> glyoxalase I with human glyoxalase I.	54
Figure 14:	Alignment of glyoxalases II.	55
Figure 15:	SDS-PAGE of active recombinantly produced <i>P. falciparum</i> glyoxalases. ..	56
Figure 16:	Dixon plots comparing competitive inhibition of (A) HBPC-GSH and (B) S- <i>p</i> -bromobenzylglutathione on <i>P. falciparum</i> glyoxalase I using the methylglyoxal-GSH adduct as substrate.	59
Figure 17:	Crystals of cGloI.	62
Figure 18:	Model of the active sites and hydrophobic binding pocket of GloI based on the crystal structure of human GloI (Cameron <i>et al.</i> , 1999a).	64
Figure 19:	Model of tGloII based on the crystal structure of human GloII.	65
Figure 20:	Model of the metal binding site of tGloII and cGloII.	66
Figure 21:	Model of the glutathione-binding site of tGloII and cGloII.	66
Figure 22:	Cornish-Bowden plot showing that compound 3 inhibits PfTrxR uncompetitively with respect to PfTrx.	68
Figure 23:	Convex isobologram indicating the antagonistic effects of compound 1 upon combination with chloroquine, methylene blue and artemisinin.	69

Figure 24:	Stage specificity of methylene blue action on the CQ resistant <i>P. falciparum</i> strain K1.	70
Figure 25:	FIC ₅₀ (left) and FIC ₉₀ -values (right) of MB and CQ determined at various dosage ratios (1:1, 1:3, and 3:1) and in independent experiments (indicated by the lines) on CQ-resistant (K1) and CQ-sensitive (3D7) strains of <i>P. falciparum</i>	74
Figure 26:	FIC ₅₀ (left) and FIC ₉₀ values (right) of MB and artemisinin at various fixed dosage ratios on different <i>P. falciparum</i> strains.	75
Figure 27:	Amino acid sequence of recombinant hexa-histidyl-tagged PfTrx indicating the two peptide fragments spanning the glutathionylated Cys ⁵⁴ (red) of interest.	78
Figure 28:	MALDI-TOF mass spectra of PfTrx peptides.	79
Figure 29:	Factors affecting parasite resistance.	81

List of Tables

Table 1:	Factors contributing to development and spread of drug resistance	11
Table 2:	Cloning and overexpression of human and <i>P. falciparum</i> glyoxalase genes...	35
Table 3:	Purification of <i>P. falciparum</i> and human glyoxalases.....	36
Table 4:	Optimization of the expression conditions for PfLipDH1 and PfLipDH2.....	36
Table 5:	Characteristics of <i>Plasmodium falciparum</i> strains employed	45
Table 6:	Kinetic properties of <i>P. falciparum</i> and human glyoxalases I	57
Table 7:	Kinetic properties of <i>P. falciparum</i> and human glyoxalases II	57
Table 8:	IC ₅₀ and K _i values of S-(N-aryl-N-hydroxycarbamoyl)glutathiones on human and <i>P. falciparum</i> glyoxalases.....	58
Table 9:	Structures of the most potent PfTrxR inhibitors; compounds 1-3 and corresponding IC ₅₀ values on <i>P. falciparum</i> TrxR and human TrxR.	67
Table 10:	Clearance of the medium from MB by <i>P. falciparum</i> parasitized erythrocytes	71
Table 11:	Effects of combination of MB with clinically-used antimalarials.....	73
Table 12 :	<i>In vitro</i> drug combination assays of the artemisinins, piperaquine and chloroquine with MB on <i>P. falciparum</i>	76

List of Schemes

Scheme 1: Structure of methylene blue	20
Scheme 2: The lipoamide dehydrogenase reaction	24

Abbreviations

➤ A _{...nm}	Absorption at ... nm
➤ ACTs	Artemisinin-based combination therapies
➤ ad	To give a concentration of; to give a volume of
➤ AGEs	Advanced glycation endproducts
➤ APS	Ammonium persulphate
➤ BlueCQ	Methylene blue + chloroquine drug combination
➤ BSA	Bovine serum albumin
➤ cpm	Counts per minute
➤ CQ	Chloroquine
➤ Da	Dalton
➤ DDT	Dichloro-diphenyl-trichloroethane
➤ DMSO	Dimethylsulfoxide
➤ DNA	Deoxyribonucleic acid
➤ dNTP	Deoxyribonucleotide triphosphate
➤ DTE	Dithioerythritol
➤ DTNB	Dithionitrobenzene
➤ EDTA	Ethylenediaminetetraacetic acid
➤ FAD	Flavin adenine dinucleotide
➤ FIC	Fractional inhibitory concentration
➤ G6PD	Glucose-6-phosphate dehydrogenase
➤ GILP	Glyoxalase I-like protein
➤ Glo	Glyoxalase
➤ GR	Glutathione reductase
➤ GSH/GSSG	Glutathione (reduced /oxidized)
➤ GST	Glutathione-S-transferase
➤ HCPC-GSH	S-(<i>N</i> -hydroxy- <i>N</i> -chlorophenylcarbamoyl)glutathione
➤ HIV/AIDS	Human immunodeficiency virus / Acquired immune deficiency syndrome
➤ HRP	Histidine rich protein
➤ HTA	Hemithioacetal
➤ IC	Inhibitory concentration
➤ IPTG	Isopropylthiogalactopyranoside

- ITN Insecticide treated nets
- LB Luria-Bertani
- LC/MS/MS Liquid chromatography / Mass spectrometry / Mass spectrometry
- LDH Lactate dehydrogenase
- MALDI-TOF Matrix-assisted laser desorption ionization – Time of flight
- MB Methylene blue
- MOPS 4-Morpholinopropane sulfonic buffer
- MSP Merozoite surface protein
- NADH/NAD⁺ Reduced /oxidized nicotinamide adenine dinucleotide
- NADPH/NADP⁺ Reduced /oxidized nicotinamide adenine dinucleotide phosphate
- NPRBC Non-parasitized red blood cells
- NTPs Nucleotide triphosphates
- PCR Polymerase chain reaction
- PEG Polyethylene glycol
- *Pf* *Plasmodium falciparum*
- PMSF Phenylmethylsulfonylfluoride
- PPP Pentose phosphate pathway
- PRBC Parasitized red blood cells
- RESA Ring-infected erythrocyte surface antigen
- RNA Ribonucleic acid
- rpm Rounds per minute
- SDLGSH S-D-lactoylglutathione
- SDS Sodium dodecyl sulphate
- SDS-PAGE Sodium dodecyl sulphate – polyacrylamide gel electrophoresis
- TEMED N,N,N',N'-Tetramethylethylenediamine
- Trx Thioredoxin
- TrxR Thioredoxin reductase
- U Unit of enzyme activity (μmol/min)
- WHO World Health Organisation

Summary

Malaria is a disease caused by protozoan parasites of the genus *Plasmodium* and is responsible for about half a billion diseases cases and 2-3 million deaths each year. Much of the parasite's success to establish persistent infections is attributed to evasion of the human immune defense system through antigenic variation and increasing development of resistance to all currently available antimalarial drugs except the artemisinins. The difference in structure and mode of action of the artemisinins underlines the fact that new antimalarial drugs – with differential modes of action – are an urgent priority in order to circumvent plasmodial resistance mechanisms in the absence of effective vaccines or vector control measures.

By means of rational drug design and re-evaluation of an ancient antimalarial drug, three new drug development strategies against the deadliest malarial parasite, *Plasmodium falciparum*, were developed within the frame of this thesis in order to design possible new mechanism drugs and prevent resistance development to artemisinin.

First, a complete functional glutathione-dependent glyoxalase (Glo) detoxification system – comprising a cytosolic GloI (cGloI), a GloI-like protein (GILP) and two GloIIs (cytosolic GloII named cGloII, and tGloII preceded by a targeting sequence) – was characterized in direct comparison with the isofunctional human host enzymes. Kinetic and structural similarities of enzymes of both systems were described; however, striking differences – especially for the GloIs – were also detected which could be exploited for drug development. Various S-(*N*-hydroxy-*N*-arylcarbamoyl)glutathiones tested as *P. falciparum* Glo inhibitors were found to be active in the lower nanomolar range and could be used as lead structures in the development of more selective inhibitors of the *P. falciparum* glyoxalase system (Akoachere *et al.*, 2005).

Secondly, the characterization of the mode of inhibition of three promising inhibitors of the previously-validated drug target *P. falciparum* thioredoxin reductase (PfTrxR) is reported in this thesis. The enzyme is a homodimeric flavoenzyme which reduces thioredoxin (Trx) via a C-terminally located CysXXXXCys pair. In this respect PfTrxR differs significantly from its human counterpart which bears a Cys-Sec redox pair at the same position. PfTrxR is essentially involved in antioxidant defence and redox regulation of the parasite and has been validated as a drug target. The inhibitors, 4-nitro-2,1,3-benzothiadiazole (IC₅₀ on PfTrxR = 2 µM), 6,7-nitroquinoxaline (IC₅₀ on PfTrxR = 2 µM), and bis-(2,4-

dinitrophenyl)sulfide (IC_{50} on PfTrxR = 0.5 μ M), showed uncompetitive inhibition with respect to both substrates, NADPH and thioredoxin. All three inhibitors were active in the lower micromolar range on the chloroquine resistant *P. falciparum* strain K1. 4-Nitro-2,1,3-benzothiadiazole was antagonistic with known antimalarials suggesting that the inhibitor uses similar routes of uptake and/or acts on related targets or biochemical pathways (Andricopulo *et al.*, 2005; Andricopulo *et al.*, submitted).

Lastly and most importantly, the renaissance of interest in the ancient antimalarial drug methylene blue (MB) led to the identification of a potential artemisinin-based combination therapy (ACT). A strong synergistic action of MB and artemisinin might be capable of fighting resistant *P. falciparum* parasites in the field. MB is active against all blood stages of both chloroquine (CQ)-sensitive and CQ-resistant *P. falciparum* strains with IC_{50} values in the lower nanomolar range. Ring stages showed the highest susceptibility. As demonstrated by high performance liquid chromatography / tandem mass spectrometry on different cell culture compartments, MB accumulates in malarial parasites. In drug combination assays, MB was found to be antagonistic with CQ and other quinoline antimalarials like piperazine and amodiaquine; with mefloquine and quinine MB showed additive effects. In contrast, synergistic effects of MB with artemisinin, artesunate, and artemether were observed for all tested parasite strains. Artemisinin/MB concentration combination ratios of 3:1 were found to be advantageous demonstrating that the combination of artemisinin with a smaller amount of MB can be recommended for reaching maximal therapeutic effects. *In vitro* data reported here indicate that combinations of MB with artemisinin (derivatives) might be a promising option for treating drug resistant malaria. Resistance development under this drug combination is unlikely to occur (Akoachere *et al.*, in press).

Taken together, the results support the feasibility of the rational development of new potential antimalarial drugs. In combination with existing and other promising new malarial-control measures, new antimalarial drugs could greatly contribute to reducing the intolerable global burden of this disease.

Zusammenfassung

Malaria ist eine parasitäre Infektionskrankheit, die von Protozoen der Gattung *Plasmodium* hervorgerufen wird. Pro Jahr gibt es über 500 Millionen Krankheitsfälle/Neuinfektionen mit 2-3 Millionen Todesfällen. Ein wichtiger Punkt in der Pathogenese der Malaria ist die Ausbildung persistierender Infektionen. Antigenetische Variation ermöglicht es dem Parasiten, das menschliche Immunsystem zu umgehen. Weiterhin sind Plasmodien in der Lage, auf die eingesetzten Malariamittel mit rascher Resistenzentwicklung zu reagieren. Deshalb kommen Neu- und Weiterentwicklung von Medikamenten in der Bekämpfung der Malaria neben Impfstoffentwicklung und Insektiziden Massnahmen gegen den Vektor eine zentrale Rolle zu. Eine Ausnahme in der zunehmenden Resistenzproblematik bildet Artemisinin, welches eine andere chemische Zusammensetzung und einen anderen Wirkmechanismus als andere gegenwärtige Malariamittel aufweist.

In Rahmen dieser Doktorarbeit wurden drei neue Arzneimittelentwicklungs-Strategien gegen den gefährlichsten human Malariaerreger, *P. falciparum*, verfolgt. Dies erfolgte anhand von rationaler Medikamententwicklung bzw. durch eine Neubewertung ehemaliger Malariamittel mit dem Ziel, mögliche neue Wirkmechanismen aufzuzeigen und Resistenzentwicklung bei Artemisinin zu verhindern.

Der erste dieser verschiedenen Angriffspunkte war die Charakterisierung neuer Arzneimittelzielmoleküle im *Plasmodium*-Stoffwechsel. Dies umfasst die Charakterisierung eines Glutathion-abhängigen Glyoxalase (Glo) Systems im Vergleich zum isofunktionellen humanen System. Dieses System hat eine zentrale Rolle im Entgiftungsstoffwechsel der Parasiten und besteht aus einer cytosolischen GloI (cGloI), einem Glo-I ähnlichen Protein (GILP), zwei GloII (cytosolische GloII (cGloII) sowie tGloII mit einer vorangestellten Targeting-Sequenz). Hier werden kinetische und strukturelle Ähnlichkeiten im humanen und Plasmodien-System beschrieben und im Sinne einer Überprüfung als möglicher Arzneimittel-Angriffsort Verschiedenheiten aufgezeigt (vor allem bei GloI). Verschiedene S-(N-Hydroxy-N-Arylcarbamoyl)Glutathion Verbindungen wurden als Inhibitoren der Glyoxalasen an *P. falciparum* getestet, sie waren im niederen nanomolaren Bereich aktiv. Somit können diese Verbindungen als Leitsubstanzen für die Entwicklung selektiver Inhibitoren des *P. falciparum*-Glyoxalase Systems dienen (Akoachere *et al.*, 2005).

Ein zweiter zentraler Punkt dieser Doktorarbeit ist die Charakterisierung des Wirkmechanismus von drei vielversprechenden Inhibitoren der bereits als Arzneimittel-Zielmolekül validierten *P. falciparum* Thioredoxinreduktase (PfTrxR). Es handelt sich um ein homodimeres Flavoenzym, welches Thioredoxin mit Hilfe eines C-terminalen CysXXXXCys-Motives reduziert. Hierbei unterscheidet es sich vom humanen Enzym, welches an der gleichen Position ein Cys-Sec Redoxpaar beinhaltet. PfTrxR ist essentiell involviert in antioxidative Abwehrmechanismen und Redoxhomöostase im Plasmodienstoffwechsel. Die Inhibitoren 4-Nitro-2,1,3-Benzothiadiazol (IC_{50} für PfTrxR = 2 μ M), 6,7-Nitroquinoxalin (IC_{50} = 2 μ M) und Bis-2,4-Dinitrophenyl)sulfid (IC_{50} = 0,5 μ M) zeigen eine unkompetitive Hemmung für die beiden Substrate NADPH und Thioredoxin. Alle drei Inhibitoren sind aktiv im niederen mikromolaren Bereich bei dem choroquinresistenten *P. falciparum* Stamm K1. 4-Nitro-2,1,3-Benzothiadiazol zeigt einen antagonistischen Wirkmechanismus mit anderen bekannten Malariamitteln; dies bedeutet, dass dieser Hemmstoff entweder einen ähnlichen Aufnahmemechanismus besitzt und/oder an verschiedenen Molekülen bzw. biochemischen Stoffwechselwegen angreift (Andricopulo *et al.*, 2005; Andricopulo *et al.*, submitted).

Im Sinne einer Neubewertung früherer Arzneimittel gegen Malaria fokussiert meine Doktorarbeit auf Methylenblau (MB) in Bezug auf eine mögliche Artemisinin-gestützte Kombinationstherapie (ACT: Artemisinin-based combination therapy). Diese Kombination aus zwei Antimalariamitteln ist ein möglicher Weg, Resistenzenentwicklungen bei *Plasmodium* zu vermeiden. Methylenblau ist aktiv gegen alle Blutstadien von *Plasmodium* sowohl an chloroquinresistenten Stämmen mit IC_{50} -Werten im niedermolaren Bereich. Hierbei zeigen Ringstadien die höchste Empfindlichkeit. Darüberhinaus akkumuliert MB in verschiedenen Zellkompartimenten, dies konnte mit Hilfe von Hochdurchsatz-Flüssigkeits-Chromatographie bzw. Tandem-Massen-Spektrometrie gezeigt werden. In Arzneimittel-Kombinations-Assays konnte nachgewiesen werden, dass MB antagonistisch zu Chloroquin und anderen Quinolinen wie Piperaquin und Amodiaquin wirkt, während es mit Mefloquin und Quinine einen additiven Effekt zeigt. Im Gegenteil dazu besitzt MB einen synergistischen Effekt mit Artemisinin, Artesunat und Artemether in allen getesteten Plasmodienstämmen. Ein Konzentrationsverhältnis von 3:1 zwischen Artemisinin und MB hat sich als vorteilhaft erwiesen. Dies verdeutlicht, dass geringe Mengen von MB empfohlen werden können, um maximalen therapeutischen Effekt zu erzielen. Diese hier berichteten *in vitro*-Daten unterstützen die Thesen, dass die Kombination aus Artemisinin (bzw. Artemisininderivaten) und MB eine vielversprechende Möglichkeit in der

Behandlung therapieresistenter Malariafälle bieten kann. Weiterhin ist eine Resistenzentwicklung gegen die Arzneimittelkombination unwahrscheinlich (Akoachere *et al.*, 2005).

Zusammenfassend kann man sagen, dass diese Resultate die Eignung der rationalen Arzneimittelentwicklung für neue Antimalariamittel unterstreichen. In Kombination mit existierenden Arzneimitteln und zusammen mit anderen Kontrollmechanismen können neue Antimalariamittel dazu beitragen, die intolerierbare, weltweite Bedrohung durch Malaria zu verringern.